01 — At a Glance
The Suppository King Nobody Talks About
- 52-Week High / Low₹244 / ₹105
- Q3 FY26 Revenue₹218 Cr
- Q3 FY26 PAT₹25 Cr
- TTM EPS₹10.33
- Annualised EPS (Q3 Avg × 4)₹8.80
- Book Value / Share₹107
- Price to Book1.86x
- Debt to Equity0.05x
- Interest Coverage15.6x
- Export %94%
Reality Check: Q3 PAT of ₹25 crore looks modest until you realize this company made that profit selling tiny pharmaceutical products in Africa. The stock is up 58% in one year, 39% in three years. Nobody in your office talked about it. Nobody on CNBC mentioned it. And that, my friends, is how quiet compounders are made.
02 — Introduction
What Do They Sell? Trust Us, You Need It More Than You Know
Bliss GVS Pharma makes suppositories, pessaries, capsules, tablets, and syrups. If you’ve never heard these words except in a health textbook, congratulations — your digestive system is either blessed or just privately independent.
Founded in 1984, this ₹2,100 crore market cap company exports pharmaceutical formulations to over 60 countries, with 94% of sales going overseas — mostly to Africa. In Africa, Bliss is not just a company; it’s practically a household name. While Indians argue about stock multiples, Bliss is busy treating malaria, fungal infections, and inflammation across the sub-Saharan region like a pharmaceutical missionary with better margins.
The company has 7 manufacturing facilities (5 in Maharashtra, 2 in Nigeria), CRISIL BBB+/Stable rating (the same rating given to well-managed small NBFCs), and ₹172 crore sitting in its bank account as of March 2025. It also contract-manufactures for Sun Pharma and Mankind — meaning it makes pills for bigger companies too. Think of it as the humble supplier everyone depends on but nobody credits.
The Africa Thing: 65% of revenue comes from African countries. This is either a huge risk or a genius move depending on whether you believe Africa’s health spending will grow faster than its population. Bliss is betting heavily that it will. Meanwhile, it’s also diversifying into CIS countries, Russia, and Europe. Baby steps out of the African comfort zone.
03 — Business Model: Making Tiny Pills, Big Profits
The Unsexy Pharma Business That Actually Makes Money
Bliss GVS doesn’t make headline-grabbing cancer drugs or miraculous antibiotics. It makes suppositories and pessaries — those tiny medical devices that travel places pills don’t. It’s the kind of product that works silently while you’re busy thinking about more important things.
The business model is beautifully simple: manufacture 150+ branded formulations, export them to countries with limited local supply, keep margins fat by being the best in your niche, and reinvest profits back into capacity. No Shark Tank drama. No venture capital. Just steady compounding.
Key strengths: (a) Product specialization — they’re the market leader in suppositories and pessaries, with EU-GMP certification and WHO endorsement for flagship brand Lonart (anti-malarial). (b) Geographic moat — they’ve been in Africa for 30+ years. That’s not a market share; that’s a relationship. (c) Contract manufacturing — they’re basically the outsourced supplier for bigger pharma companies, which provides revenue diversification and stability.
Africa Revenue65%FY25 contribution
Export %94%of total sales
Branded Products150+across 60+ countries
Operating Margin Secret: In FY25, they hit 20% EBITDA margin — up from 16% in FY23. How? Warehouse optimization, supply chain tightening, and reduced logistics costs. They didn’t invent a new drug; they just optimized every step of existing operations. Boring. Effective. Profitable.
04 — Financials Overview
Q3 FY26: Steady Eddy or Boring?
Result type: Quarterly Results | Q3 FY26 EPS: ₹2.20 | Avg Q1–Q3 EPS: (₹4.08+₹2.58+₹2.20)/3 = ₹2.95 | Annualised EPS: ₹11.80
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 218 | 210 | 244 | +3.8% | -10.7% |
| Operating Profit | 35 | 30 | 43 | +16.7% | -18.6% |
| Operating Margin % | 16% | 14% | 18% | +200 bps | -200 bps |
| PAT | 25 | 26 | 29 | -3.8% | -13.8% |
| EPS (₹) | 2.20 | 2.26 | 2.58 | -2.7% | -14.7% |
Q3 Reality: Revenue up 3.8% YoY but down 10.7% QoQ. PAT actually down 3.8% YoY. This is what happens when you’re a small-cap pharmaceutical company exporting to Africa — quarterly numbers dance like monsoon rainfall. Not concerning, just real.
The TTM Story Is Better: TTM EPS at ₹10.33 looks healthier. The company is now averaging ₹868 crore in annual revenue and ₹114 crore in annual net profit. At ₹199 stock price, the TTM P/E is 19.3x. For a company growing revenue at 7% and profit at 38% (3-year basis), this isn’t cheap but it’s not expensive either.
💬 Q3 showed weakness — revenue down QoQ, profit down YoY. Is this a seasonal thing because African ordering patterns are weird, or has growth momentum slowed? Anyone tracking African pharma trends?
05 — Valuation: The Fair Value Math
Is ₹199 Fair Value or Fantasy?
